Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of BMS-986340 alone and in combination with nivolumab or docetaxel in advanced solid tumors
MOH_2023-03-29_012348Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of imzokitug in Nonhematologic neoplasms (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability of BMS-986340 alone and in combination. Started Jan 2023; status: active, not recruiting.
02
Drugs
imzokitug
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2023-03-29_012348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-29_012348.